Assay development optimisation & technology

By Dr Shailendra Singh, founder and CEO of Cellomatics Biosciences. Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. The number of new cases recorded between 2016 and 2018 was 375,400, with 167,142 deaths caused by cancer between 2017 and 2019. Half of people diagnosed with […]

A new collaboration aims to accelerate development of advanced G-protein coupled receptor (GPCR)-targeting therapeutics for cachexia caused by cancer and other chronic conditions.  Orbit Discovery has entered a partnership with Endevica Bio following the release of data proving that the company’s lead compound is safe and well-tolerated in Phase I trials.  Endevica’s technology platform allows […]

This paid-for advertorial by Aurora Microplates appeared in DDW Volume 24 – Issue 1, Winter 2022/2023 Aurora Microplates is focused on making the highest quality, highest performing microplates available. The company uses the best materials, the cleanest and most precise moulding operations and facilities to deliver high performance microplates in a timely fashion.   Pure […]

This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals.  This kit is the only commercial ELISA kit […]

Markus Gershater, CSO and Co-Founder of Synthace discusses how technologies such as AI and automation are helping advance biotech and drug discovery.  On June 5th, 1833, Charles Babbage presented a small working part of his “Difference Engine No 1” to a group of interested onlookers. Sitting in the audience was Ada Lovelace, a tack-sharp 17-year-old mathematician. Fascinated by […]

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing drug toxicity: new approaches and […]

The HepGo Assay-ready 3D Liver Spheroid Kit leverages Corning Life Science’s 3D cell culture technology in liver biology and ADME/Tox. Corning has developed an all-in-one solution for the development of 3D liver models that has been designed to better recapitulate in vivo behaviour. The kit is said to deliver a more physiologically relevant model over […]

PerkinElmer is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by using […]

The Native Antigen Company has announced the launch of its SARS-CoV-2 Neutralisation Assay Development Kit. The kit can be used to identify and qualitatively assess the ability of antibodies to neutralise SARS-CoV-2-receptor binding, to support research into variants and their effects on natural and vaccine-induced patient immunity. The kit contains all the key reagents required […]

Drug discovery company BellBrook Labs has been awarded a $300,000 Phase I Small Business Innovative Research grant to develop and validate HTS assays for the discovery of small-molecule antagonists of TREX1. Immunotherapy approaches such as immune checkpoint blockade are said to be transforming oncology. However, many patients do not respond to existing agents, and new therapeutic […]

Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox, Bio-Rad Immunoassays Marketing Manager, Life […]

Patricia Ahrweiler, Field Marketing Manager, Gyros Protein Technologies explains how its Gyrolab Bioaffy 4000 CD extends Gyrolab assay sensitivity to the low picogram level for improved analysis of biomarkers Biomarker research has accelerated in recent years, driving the development of novel biomarker candidates and panels for the study of a range of diseases. A case in […]

The Winter 2020/21 issue of DDW is now available in print and via the DDW App, featuring the latest innovation and insight from the drug discovery and development community. This season’s issue contains features on vaccines and immunology, AI and the US biotech sector plus expertise from companies such as PerkinElmer, Thermo Fisher Scientific and […]

Today’s episode on the topic of Innovation and Opportunity in Drug Discovery, covers 3 articles taken from the most recent Fall issue of DDW. These articles are titled: Japanese drug development: Where is the innovation, Where are the opportunities in global drug discovery, and New for Old: The value behind drug repurposing. These articles were written by Lu […]

Dr J. Mark Treherne, Dr Christian Pernstich and Dr Michael Jones examine how the controlled release of proteins will  improve the reproducibility of cell-based drug discovery screens? Cell-based screening systems are now routinely incorporated as pivotal decision-making assays much earlier into the drug discovery process across most therapeutic areas and increasingly so for more complex […]

LSBio, a provider of antibodies and life science research reagents, has acquired UK-based Absolute Antibody, its sister company Kerafast. LSBio provides IHC-validated reagent antibodies and services to the global community of academic, pharmaceutical and biotech researchers. The company has built a catalogue of more than 750,000 reagent antibodies, assay kits, proteins, and biochemicals, and its […]